Revolving door between the US Government and Industry
Congressman Burton critical of Vaccine Approval Process
Staff Report detailing conflicts of interest
Conflicts-Of-Interest in Drug Studies Sneaking Back Into Medical Journals, Say Investigators, and more at other links on that page.
Merck's Quiet Effort - influencing mandating of chicken pox vaccine in Ohio
Merck paid legislators, hospitals, docs and organizations!
From: Dawn Richardson, PROVE
This is a phenomenal letter written by a parent of a vaccine injured child in response to an editorial comment published on WebMD. It clearly illustrates the incestuous ties some of those who make vaccine decisions for our children have with drug companies. These are the very people who are critical of the parents and elected representatives who are doing such a great job shedding light on some of the dangers of vaccines because of the threat the truth poses to their pocketbooks. The internet (source of all this information) is a wonderful thing.
----------------------------------------- In Reply to Editorial Comment from: Wayne L. Pines Re: Congressional Hearings on Vaccines and Autism
Dr Marcia Angell, former editor of the New England Journal of Medicine, was interviewed. She says many significant things, but note this in particular as the core of it:
"It used to be that drug companies simply gave grants to academic medical centres for the use of their clinical researchers to do a study and that was it. It was at arm's length. The researcher did a study and he or she published the results, whatever those results would be. Now, it's very, very different. The drug companies increasingly design the studies. They keep the data. They don't even let the researchers see the data. They analyse the data. They decide whether they're going to even publish the data at the end of it. They sign contracts with researchers and with academic medical centres saying that they don't get to publish their work unless they get permission from the drug company. So, you can see that the distortion starts even before publication. It starts in determining what's going to be published and what isn't going to be published. This is no longer arm's length. It's treating the researchers and the academic medical centres as though they were hired guns or technicians or something. They just do the work. And the drug company will decide what the data show, what the conclusions are and whether it will even be published."
During 1999 the following groups provided funds to IAC:
Government:
Centers for Disease Control and Prevention
Private Sources:
Approximately two thousand private individuals
Professional Organizations:
American Pharmaceutical Association
Corporations:
Chiron Corporation
GlaxoWellcome
Merck & Co.
Nabi
North American Vaccine
Pasteur Merieux Connaught
SmithKline Beecham
Wyeth Lederle Vaccines
http://www.nejm.org/content/2000/0342/0020/1462.asp URL no longer works
Supported by Bristol-Myers Squibb. Dr. Keller has served as a consultant to or received honorariums from Pfizer, Bristol-Myers Squibb, Forest Laboratories/Parke-Davis, Wyeth - Ayerst, Merck, Janssen, Eli Lilly, Organon, and Pharmacia - Upjohn. He has received research grants from Wyeth - Ayerst, SmithKline Beecham, Upjohn, Pfizer, Bristol-Myers Squibb, Merck, Forest Laboratories, Zeneca, and Organon. He has served on the advisory board of Wyeth - Ayerst, Pfizer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories/Parke-Davis, Organon, SmithKline Beecham, Merck, Janssen, Mitsubishi Pharmaceuticals, Zeneca, Scirex, and Otsuka. Dr. Klein has served as a consultant to Bristol-Myers Squibb. Dr. Dunner has served as a consultant to Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, and Eli Lilly. He has received research grants from Bristol-Myers Squibb, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Forest Laboratories, Glaxo Wellcome, and Wyeth - Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, Eli Lilly, Organon, and Wyeth - Ayerst. Dr. Gelenberg has received grants and research support from Bristol-Myers Squibb, Organon, Pfizer, Lilly Research Laboratories, Janssen, Merck Sharp Dohme, SmithKline Beecham, Wyeth - Ayerst, Hoechst Marion Roussel, and Forest Laboratories. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Pfizer, SmithKline Beecham, Janssen, Lilly, Forest Laboratories, and Parke-Davis. He is a stockholder or has other ownership interest in Pfizer, Warner-Lambert, and Eli Lilly. He has served as a consultant to Eli Lilly, Scios, Forest Laboratories, Parke-Davis, Pfizer, Janus Pharmaceuticals, Best Practice, and Bristol-Myers Squibb. Dr. Markowitz has received speaker's honorariums from Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, and Pfizer. Dr. Nemeroff has been a consultant to or received honorariums from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi, Neurocrine Biosciences, Organon, Otsuka, Pfizer, Pharmacia - Upjohn, Sanofi, SmithKline Beecham, Solvay, and Wyeth - Ayerst. He has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Organon, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Russell has been a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Janssen, Eli Lilly, Pfizer, and Quintiles. He has received research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Parke-Davis, Pharmacia - Upjohn, Pfizer, SmithKline Beecham, Wyeth - Ayerst, Shire, and Quintiles. Dr. Thase has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome/Cerenex Pharmaceuticals, Merck, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. He has received grant and research support from Bristol-Myers Squibb, Lipha Pharmaceuticals, Merck, Organon, Pharmacia - Upjohn, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, Glaxo Wellcome/Cerenex Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Trivedi has received research grants from Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Janssen, Johnson & Johnson, MeadJohnson, Parke-Davis, Pfizer, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Forest Laboratories, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst. Dr. Zajecka has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, Organon, Otsuka America, Parke-Davis, Pfizer, Pharmacia - Upjohn, and Sanofi Research. He has served as a consultant to or has served on the advisory board of Abbott, Bristol-Myers Squibb, and Eli Lilly. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, SmithKline Beecham, Upjohn, and Wyeth - Ayerst. Dr. Blalock has served as a consultant to Bristol-Myers Squibb. Dr. DeBattista has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Parke-Davis, Pfizer, Scios, SmithKline Beecham, Wyeth - Ayerst, and Organon. He has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Pfizer, the National Alliance for Research on Schizophrenia and Depression, Pharmacia - Upjohn, PharmaPrint/ABA, SmithKline Beecham, and Wyeth - Ayerst. He has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, and PharmaPrint. Dr. Fawcett has received grants and research support from Abbott, Bristol-Myers Squibb, Glaxo, Eli Lilly, Organon, Pfizer, SmithKline Beecham, Wyeth - Ayerst, and Zeneca. He has served as a consultant to Abbott, Bristol-Myers Squibb, Eli Lilly, EM Industries, Forest Laboratories, Glaxo Wellcome, Pfizer, Pharmacia - Upjohn, and SmithKline Beecham. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, Pharmacia - Upjohn, SmithKline Beecham, and Wyeth - Ayerst. Dr. Hirschfeld has received grants and research support from Abbott, Bristol-Myers Squibb, Organon, and Pfizer. He has served as a consultant to or on the advisory board of Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Forest Laboratories, Eli Lilly, Pfizer, SmithKline Beecham, Janssen, Organon, Parke-Davis, and Pharmacia - Upjohn. Dr. Kocsis has had research contracts with Bristol-Myers Squibb, Pfizer, Forest Laboratories, Eli Lilly, and Wyeth - Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, Forest Laboratories, and Eli Lilly. He owns stock in Pfizer and Forest Laboratories. Dr. Kornstein has received research grants from Bristol-Myers Squibb, Pfizer, Eli Lilly, Glaxo Wellcome, Forest Laboratories, Mitsubishi Pharmaceuticals, and Biovail. She has served as a consultant to Bristol-Myers Squibb, Pfizer, Eli Lilly, and Pharmacia - Upjohn. She has received honorariums from Bristol-Myers Squibb, Pfizer, and Glaxo Wellcome. Dr. Ninan has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Pharmacia - Upjohn, SmithKline Beecham, and Solvay. He has served as a consultant to Pfizer, TAPPharma, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, Janssen, and Wyeth - Ayerst. Dr. Rothbaum has served as a consultant to Bristol-Myers Squibb and Pfizer. She has been a member of the advisory board of and a speakers' bureau sponsored by Pfizer. Dr. Rush has received grants and research support from Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Novartis, Organon, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Wyeth - Ayerst, and Zeneca. He has served as a consultant to Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Merck, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. Dr. Schatzberg has served as a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Corcept Therapeutics, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, Sanofi, Scirex, SmithKline Beecham, Solvay, and Wyeth - Ayerst. He has received research support from Bristol-Myers Squibb, Pfizer, and SmithKline Beecham. He has equity ownership in Corcept, Merck, Pfizer, and Scirex.
The Medical Monopoly: Protecting Consumers or Limiting Competition? Sue A. Blevins
The Medical Monopoly:
Your Tax Dollars Limit the Competition
by Richard Leviton
Merck paid legislators, hospitals, docs and organizations!
